ERBB2 and breast cancer: The probabilistic sensitivity analysis of T-DXd revealed that for all advanced BC patients with HER2-Low, HER2+, and HER2-status, the probability of cost-effectiveness of T-DXd was 81.10%, 82.27%, and 73.78%, respectively, at $100,000/QALY.